Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Aug 31;12(8):477-480.
doi: 10.1093/jpids/piad052.

Safety of Re-dosing Nirsevimab Prior to RSV Season 2 in Children With Heart or Lung Disease

Joseph B Domachowske  1 , Yue Chang  2 , Victoria Atanasova  3 , Fernando Cabañas  4 , Kenji Furuno  5 , Kim A Nguyen  6 , Irfana Banu  7 , Robert J Kubiak  8 , Amanda Leach  2 , Vaishali S Mankad  9 , Manish Shroff  10 , Therese Takas  2 , Tonya Villafana  2 , Ulrika Wählby Hamrén  11
Affiliations

Safety of Re-dosing Nirsevimab Prior to RSV Season 2 in Children With Heart or Lung Disease

Joseph B Domachowske et al. J Pediatric Infect Dis Soc. .

Abstract

In children with congenital heart disease and/or chronic lung disease entering their second respiratory syncytial virus (RSV) season, 200 mg nirsevimab had a similar safety profile to that of palivizumab and resulted in nirsevimab serum exposures associated with efficacy in healthy infants, supporting efficacy in this population at risk of severe RSV disease.

Keywords: monoclonal antibody; nirsevimab; palivizumab; pharmacokinetics; respiratory syncytial virus.

PubMed Disclaimer

References

    1. Griffin MP, Khan AA, Esser MT, et al. . Safety, tolerability, and pharmacokinetics of MEDI8897, the respiratory syncytial virus prefusion F-targeting monoclonal antibody with an extended half-life, in healthy adults. Antimicrob Agents Chemother 2017; 61:e01714–16. - PMC - PubMed
    1. Li Y, Wang X, Blau DM, et al. ; Respiratory Virus Global Epidemiology Network. Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in children younger than 5 years in 2019: a systematic analysis. Lancet 2022; 399:2047–64. - PMC - PubMed
    1. Griffin MP, Yuan Y, Takas T, et al. ; Nirsevimab Study Group. Single-dose nirsevimab for prevention of RSV in preterm infants. N Engl J Med 2020; 383:415–25. - PubMed
    1. Hammitt LL, Dagan R, Yuan Y, et al. ; MELODY Study Group. Nirsevimab for prevention of RSV in healthy late-preterm and term infants. N Engl J Med 2022; 386:837–46. - PubMed
    1. Muller WJ, Madhi SA, Seoane Nuñez B, et al. ; MELODY Study Group. Nirsevimab for prevention of RSV in term and late-preterm infants. N Engl J Med 2023; 388:1533–4. - PubMed

Grants and funding